The importance of chemotherapy dose intensity in lung cancer

This publication has 38 references indexed in Scilit:

• Dose and schedule as determinants of outcomes in chemotherapy for breast cancer
  Seminars in Oncology, 2004
• New treatment strategies for aggressive lymphoma
  Seminars in Oncology, 2004
• Cancer Statistics, 2004
  CA: A Cancer Journal for Clinicians, 2004
• Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975
  Journal of Clinical Oncology, 2003
• Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
  Journal of Clinical Oncology, 2003
• O-275 Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21)
  Lung Cancer, 2003
• O-49 Age-specific subanalysis of ECOG 1594: Fit elderly patietns (70–80 yrs) with NSCLC do as well as younger patients (<70)
  Lung Cancer, 2003
• Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
  Journal of Clinical Oncology, 2003
• A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer
  European Journal Of Cancer, 1999
• Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
  New England Journal of Medicine, 1995